U.S. Markets open in 56 mins

Ameri Holdings, Inc. (AMRH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8500+0.0100 (+0.54%)
At close: 4:00PM EDT

1.8501 0.00 (0.01%)
Before hours: 8:06AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.8400
Open1.8900
Bid1.8000 x 1100
Ask0.0000 x 1000
Day's Range1.7900 - 1.8900
52 Week Range0.6260 - 7.3500
Volume282,790
Avg. Volume1,813,848
Market Cap10.02M
Beta (5Y Monthly)5.85
PE Ratio (TTM)N/A
EPS (TTM)-2.4120
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 23, 2008
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AMERI Holdings Files Amended Registration Statement On Form S-4
    PR Newswire

    AMERI Holdings Files Amended Registration Statement On Form S-4

    AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced that it has filed an Amended Registration Statement on Form S-4 ("Amended S-4") with the Securities and Exchange Commission ("SEC"), which includes a preliminary proxy statement/prospectus, in connection with the Company's proposed tender agreement with Jay Pharma.

  • Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma
    PR Newswire

    Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma

    AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri"), announced that its proposed amalgamation partner Jay Pharma Inc. ("Jay Pharma" or "the Company") has announced the addition of new senior staff as the Company prepares to file two new investigational new drug (IND) applications for the treatment of radiodermatitis and glioblastoma multiforme (GBM).

  • Ameri Holdings Provides Update On Pending Transaction With Jay Pharma Inc.
    PR Newswire

    Ameri Holdings Provides Update On Pending Transaction With Jay Pharma Inc.

    AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri" or the "Company"), announced that the Company is continuing to work through the regulatory review process towards finalizing the proposed amalgamation transaction with Jay Pharma, Inc. ("Jay Pharma"), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care (the "Amalgamation"). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri's current Series A Preferred Equity Holders (the "Spin-Off," and collectively, with the Amalgamation, the "Transactions"). The Transactions, which were originally expected to close in the first half of 2020, remain subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions. Ameri filed a Registration Statement on Form S-4 and preliminary Proxy Statement on May 27, 2020, with the Securities and Exchange Commission ("SEC") in connection with Ameri's proposed amalgamation agreement with Jay Pharma (the "transaction"). Once the required regulatory approvals have been obtained, the Company intends to immediately set a date for a special meeting for its shareholders to approve the proposals associated with the Transactions, deliver the final Proxy Statement to its shareholders, and then proceed to expeditiously close the Transactions.